We are analyzing https://link.springer.com/article/10.1186/s12943-021-01401-y.

Title:
An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks | Molecular Cancer
Description:
Background Adenosine deaminases acting on RNA (ADARs) modify many cellular RNAs by catalyzing the conversion of adenosine to inosine (A-to-I), and their deregulation is associated with several cancers. We recently showed that A-to-I editing is elevated in thyroid tumors and that ADAR1 is functionally important for thyroid cancer cell progression. The downstream effectors regulated or edited by ADAR1 and the significance of ADAR1 deregulation in thyroid cancer remain, however, poorly defined. Methods We performed whole transcriptome sequencing to determine the consequences of ADAR1 deregulation for global gene expression, RNA splicing and editing. The effects of gene silencing or RNA editing were investigated by analyzing cell viability, proliferation, invasion and subnuclear localization, and by protein and gene expression analysis. Results We report an oncogenic function for CDK13 in thyroid cancer and identify a new ADAR1-dependent RNA editing event that occurs in the coding region of its transcript. CDK13 was significantly over-edited (c.308A > G) in tumor samples and functional analysis revealed that this editing event promoted cancer cell hallmarks. Finally, we show that CDK13 editing increases the nucleolar abundance of the protein, and that this event might explain, at least partly, the global change in splicing produced by ADAR1 deregulation. Conclusions Overall, our data support A-to-I editing as an important pathway in cancer progression and highlight novel mechanisms that might be used therapeutically in thyroid and other cancers.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

cancer, pubmed, cdk, editing, adar, splicing, cells, article, thyroid, rna, google, scholar, cas, cell, fig, central, cal, analysis, genes, alternative, tpc, edited, events, atoi, observed, expression, data, gene, sicontrol, event, silencing, rnaseq, tumor, invasion, protein, nuclear, siadar, oncogenic, regulation, carcinoma, knockdown, global, localization, results, sites, lines, differential, progression, performed, proliferation,

Topics {✒️}

leibniz-institut dsmz-german collection article ramírez-moya cyclin-dependent kinase implicated article download pdf pid2019-105303rb-i00/aei/10 triple-negative breast cancer rna-seq variant calling regulates mir-200 activity adar1 steady-state expression rna-seq pipeline implemented innate immune response adenosine deaminases acting gov/geo/query/acc 75-bp paired-end reads direct cis-element editing stably expressing cdk13-wt rna-seq analysis showing high throughput rna-sequencing full access alternative pre-mrna splicing replicate rna-seq data main cancer hallmarks develop de novo hypoxia-induced tpm2 methylation adar1-mediated rna editing regulatory n-terminal region adar-mediated rna editing rna-seq results reveal comprehensive splice-site analysis sr-related protein implicated pre-mrna splicing factors cdk13 n-terminal region quantitative reverse transcription-pcr double-stranded rnas rna-sequencing sds-page inhibited colony formation regulates alternative splicing cis-acting elements sr protein-specific kinases human disease phenotypes rna-seq analysis demonstrated stably-transduced cdk13-wt post-transcriptional conversion cdk13 wt/edit ratio nucleic acids res adar1-dependent activity wt-cdk13 stimulated proliferation equivalent adar1-silenced cells adenosine deaminase acting privacy choices/manage cookies

Questions {❓}

How did alternative splicing evolve?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks
         description:Adenosine deaminases acting on RNA (ADARs) modify many cellular RNAs by catalyzing the conversion of adenosine to inosine (A-to-I), and their deregulation is associated with several cancers. We recently showed that A-to-I editing is elevated in thyroid tumors and that ADAR1 is functionally important for thyroid cancer cell progression. The downstream effectors regulated or edited by ADAR1 and the significance of ADAR1 deregulation in thyroid cancer remain, however, poorly defined. We performed whole transcriptome sequencing to determine the consequences of ADAR1 deregulation for global gene expression, RNA splicing and editing. The effects of gene silencing or RNA editing were investigated by analyzing cell viability, proliferation, invasion and subnuclear localization, and by protein and gene expression analysis. We report an oncogenic function for CDK13 in thyroid cancer and identify a new ADAR1-dependent RNA editing event that occurs in the coding region of its transcript. CDK13 was significantly over-edited (c.308A > G) in tumor samples and functional analysis revealed that this editing event promoted cancer cell hallmarks. Finally, we show that CDK13 editing increases the nucleolar abundance of the protein, and that this event might explain, at least partly, the global change in splicing produced by ADAR1 deregulation. Overall, our data support A-to-I editing as an important pathway in cancer progression and highlight novel mechanisms that might be used therapeutically in thyroid and other cancers.
         datePublished:2021-09-08T00:00:00Z
         dateModified:2021-09-08T00:00:00Z
         pageStart:1
         pageEnd:20
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12943-021-01401-y
         keywords:
            ADAR1
            A-to-I editing
            Cancer
            CDK13
            Splicing
            Cancer Research
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig6_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig7_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig8_HTML.png
         isPartOf:
            name:Molecular Cancer
            issn:
               1476-4598
            volumeNumber:20
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Julia Ramírez-Moya
               url:https://orcid.org/0000-0002-2458-2186
               affiliation:
                     name:Universidad Autónoma de Madrid (UAM)
                     address:
                        name:Instituto, de Investigaciones Biomédicas “Alberto Sols”; Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Madrid, Spain
                        type:PostalAddress
                     type:Organization
                     name:Harvard Medical School
                     address:
                        name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
                     name:Harvard Medical School Initiative for RNA Medicine
                     address:
                        name:Stem Cell Program, Division of Hematology/Oncology, Boston Children’s Hospital, Departments of Biological Chemistry and Molecular Pharmacology, and Pediatrics, Harvard Medical School, Harvard Medical School Initiative for RNA Medicine, Boston, USA
                        type:PostalAddress
                     type:Organization
                     name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII)
                     address:
                        name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII), Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Christos Miliotis
               affiliation:
                     name:Harvard Medical School
                     address:
                        name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Allison R. Baker
               affiliation:
                     name:Harvard Medical School
                     address:
                        name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Richard I. Gregory
               affiliation:
                     name:Harvard Medical School Initiative for RNA Medicine
                     address:
                        name:Stem Cell Program, Division of Hematology/Oncology, Boston Children’s Hospital, Departments of Biological Chemistry and Molecular Pharmacology, and Pediatrics, Harvard Medical School, Harvard Medical School Initiative for RNA Medicine, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Frank J. Slack
               affiliation:
                     name:Harvard Medical School
                     address:
                        name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Pilar Santisteban
               url:http://orcid.org/0000-0002-2758-796X
               affiliation:
                     name:Universidad Autónoma de Madrid (UAM)
                     address:
                        name:Instituto, de Investigaciones Biomédicas “Alberto Sols”; Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Madrid, Spain
                        type:PostalAddress
                     type:Organization
                     name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII)
                     address:
                        name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII), Madrid, Spain
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks
      description:Adenosine deaminases acting on RNA (ADARs) modify many cellular RNAs by catalyzing the conversion of adenosine to inosine (A-to-I), and their deregulation is associated with several cancers. We recently showed that A-to-I editing is elevated in thyroid tumors and that ADAR1 is functionally important for thyroid cancer cell progression. The downstream effectors regulated or edited by ADAR1 and the significance of ADAR1 deregulation in thyroid cancer remain, however, poorly defined. We performed whole transcriptome sequencing to determine the consequences of ADAR1 deregulation for global gene expression, RNA splicing and editing. The effects of gene silencing or RNA editing were investigated by analyzing cell viability, proliferation, invasion and subnuclear localization, and by protein and gene expression analysis. We report an oncogenic function for CDK13 in thyroid cancer and identify a new ADAR1-dependent RNA editing event that occurs in the coding region of its transcript. CDK13 was significantly over-edited (c.308A > G) in tumor samples and functional analysis revealed that this editing event promoted cancer cell hallmarks. Finally, we show that CDK13 editing increases the nucleolar abundance of the protein, and that this event might explain, at least partly, the global change in splicing produced by ADAR1 deregulation. Overall, our data support A-to-I editing as an important pathway in cancer progression and highlight novel mechanisms that might be used therapeutically in thyroid and other cancers.
      datePublished:2021-09-08T00:00:00Z
      dateModified:2021-09-08T00:00:00Z
      pageStart:1
      pageEnd:20
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12943-021-01401-y
      keywords:
         ADAR1
         A-to-I editing
         Cancer
         CDK13
         Splicing
         Cancer Research
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig6_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig7_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01401-y/MediaObjects/12943_2021_1401_Fig8_HTML.png
      isPartOf:
         name:Molecular Cancer
         issn:
            1476-4598
         volumeNumber:20
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Julia Ramírez-Moya
            url:https://orcid.org/0000-0002-2458-2186
            affiliation:
                  name:Universidad Autónoma de Madrid (UAM)
                  address:
                     name:Instituto, de Investigaciones Biomédicas “Alberto Sols”; Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Madrid, Spain
                     type:PostalAddress
                  type:Organization
                  name:Harvard Medical School
                  address:
                     name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
                  name:Harvard Medical School Initiative for RNA Medicine
                  address:
                     name:Stem Cell Program, Division of Hematology/Oncology, Boston Children’s Hospital, Departments of Biological Chemistry and Molecular Pharmacology, and Pediatrics, Harvard Medical School, Harvard Medical School Initiative for RNA Medicine, Boston, USA
                     type:PostalAddress
                  type:Organization
                  name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII)
                  address:
                     name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII), Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Christos Miliotis
            affiliation:
                  name:Harvard Medical School
                  address:
                     name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Allison R. Baker
            affiliation:
                  name:Harvard Medical School
                  address:
                     name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Richard I. Gregory
            affiliation:
                  name:Harvard Medical School Initiative for RNA Medicine
                  address:
                     name:Stem Cell Program, Division of Hematology/Oncology, Boston Children’s Hospital, Departments of Biological Chemistry and Molecular Pharmacology, and Pediatrics, Harvard Medical School, Harvard Medical School Initiative for RNA Medicine, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Frank J. Slack
            affiliation:
                  name:Harvard Medical School
                  address:
                     name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Pilar Santisteban
            url:http://orcid.org/0000-0002-2758-796X
            affiliation:
                  name:Universidad Autónoma de Madrid (UAM)
                  address:
                     name:Instituto, de Investigaciones Biomédicas “Alberto Sols”; Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Madrid, Spain
                     type:PostalAddress
                  type:Organization
                  name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII)
                  address:
                     name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII), Madrid, Spain
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Molecular Cancer
      issn:
         1476-4598
      volumeNumber:20
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Universidad Autónoma de Madrid (UAM)
      address:
         name:Instituto, de Investigaciones Biomédicas “Alberto Sols”; Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Madrid, Spain
         type:PostalAddress
      name:Harvard Medical School
      address:
         name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
         type:PostalAddress
      name:Harvard Medical School Initiative for RNA Medicine
      address:
         name:Stem Cell Program, Division of Hematology/Oncology, Boston Children’s Hospital, Departments of Biological Chemistry and Molecular Pharmacology, and Pediatrics, Harvard Medical School, Harvard Medical School Initiative for RNA Medicine, Boston, USA
         type:PostalAddress
      name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII)
      address:
         name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII), Madrid, Spain
         type:PostalAddress
      name:Harvard Medical School
      address:
         name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
         type:PostalAddress
      name:Harvard Medical School
      address:
         name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
         type:PostalAddress
      name:Harvard Medical School Initiative for RNA Medicine
      address:
         name:Stem Cell Program, Division of Hematology/Oncology, Boston Children’s Hospital, Departments of Biological Chemistry and Molecular Pharmacology, and Pediatrics, Harvard Medical School, Harvard Medical School Initiative for RNA Medicine, Boston, USA
         type:PostalAddress
      name:Harvard Medical School
      address:
         name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
         type:PostalAddress
      name:Universidad Autónoma de Madrid (UAM)
      address:
         name:Instituto, de Investigaciones Biomédicas “Alberto Sols”; Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Madrid, Spain
         type:PostalAddress
      name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII)
      address:
         name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII), Madrid, Spain
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Julia Ramírez-Moya
      url:https://orcid.org/0000-0002-2458-2186
      affiliation:
            name:Universidad Autónoma de Madrid (UAM)
            address:
               name:Instituto, de Investigaciones Biomédicas “Alberto Sols”; Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Madrid, Spain
               type:PostalAddress
            type:Organization
            name:Harvard Medical School
            address:
               name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
            name:Harvard Medical School Initiative for RNA Medicine
            address:
               name:Stem Cell Program, Division of Hematology/Oncology, Boston Children’s Hospital, Departments of Biological Chemistry and Molecular Pharmacology, and Pediatrics, Harvard Medical School, Harvard Medical School Initiative for RNA Medicine, Boston, USA
               type:PostalAddress
            type:Organization
            name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII)
            address:
               name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII), Madrid, Spain
               type:PostalAddress
            type:Organization
      name:Christos Miliotis
      affiliation:
            name:Harvard Medical School
            address:
               name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      name:Allison R. Baker
      affiliation:
            name:Harvard Medical School
            address:
               name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      name:Richard I. Gregory
      affiliation:
            name:Harvard Medical School Initiative for RNA Medicine
            address:
               name:Stem Cell Program, Division of Hematology/Oncology, Boston Children’s Hospital, Departments of Biological Chemistry and Molecular Pharmacology, and Pediatrics, Harvard Medical School, Harvard Medical School Initiative for RNA Medicine, Boston, USA
               type:PostalAddress
            type:Organization
      name:Frank J. Slack
      affiliation:
            name:Harvard Medical School
            address:
               name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Pilar Santisteban
      url:http://orcid.org/0000-0002-2758-796X
      affiliation:
            name:Universidad Autónoma de Madrid (UAM)
            address:
               name:Instituto, de Investigaciones Biomédicas “Alberto Sols”; Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Madrid, Spain
               type:PostalAddress
            type:Organization
            name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII)
            address:
               name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII), Madrid, Spain
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Instituto, de Investigaciones Biomédicas “Alberto Sols”; Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Madrid, Spain
      name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
      name:Stem Cell Program, Division of Hematology/Oncology, Boston Children’s Hospital, Departments of Biological Chemistry and Molecular Pharmacology, and Pediatrics, Harvard Medical School, Harvard Medical School Initiative for RNA Medicine, Boston, USA
      name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII), Madrid, Spain
      name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
      name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
      name:Stem Cell Program, Division of Hematology/Oncology, Boston Children’s Hospital, Departments of Biological Chemistry and Molecular Pharmacology, and Pediatrics, Harvard Medical School, Harvard Medical School Initiative for RNA Medicine, Boston, USA
      name:Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
      name:Instituto, de Investigaciones Biomédicas “Alberto Sols”; Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Madrid, Spain
      name:Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII), Madrid, Spain

External Links {🔗}(319)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.93s.

LINK . SPRINGER . COM {}